Detection of 6 mutations associated with dihydropyrimidine dehydrogenase deficiency.
Prognostic and predictive molecular in vitro test to determine the risk of recurrence and the absolute benefit of chemotherapy over the next 15 and 10 years, respectively, in patients with ER+/HER2- primary breast cancer.
Genvinset® HLA B57v5
Kit for detecting the HLA-B*57:01 alleles by Real-Time PCR using TaqMan® probes technology Information about the product Abacavir sulfate is […]
Genvinset® HLA DQA1*05
Kit for the detection of HLA-DQA1*05 allele by Real-Time PCR technology using TaqMan® probes technology. Information about the product Several […]
The most comprehensive tumor test to determine Homologous Recombination Deficiency (HDR) Status by studying the BRCA genes in patients with ovarian cancer.